Form 8-K

8-K — GILEAD SCIENCES, INC.

Accession: 0001104659-26-049874

Filed: 2026-04-28

Period: 2026-04-28

CIK: 0000882095

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2612748d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2612748d1_ex99-1.htm)

GRAPHIC (tm2612748d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2612748d1_8k.htm · Sequence: 1

false

0000882095

2026-04-28

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant

to Section 13 or

15(d) of

The Securities Exchange

Act of 1934

DATE

OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 28, 2026

GILEAD SCIENCES, INC.

(Exact name of registrant

as specified in its charter)

Delaware

0-19731

94-3047598

(State or other jurisdiction

incorporation)

(Commission File No.)

(IRS Employer

Identification No.)

333 Lakeside Drive, Foster City, California

(Address of principal executive offices)

94404

(Zip Code)

(650)

574-3000

(Registrant’s telephone number, including

area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of

the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which

registered

Common Stock, par value, $0.001 per share

GILD

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934

(17 CFR §240.12b-2).

Emerging

growth company ¨

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01.

Regulation FD Disclosure.

On April 28, 2026, Gilead Sciences, Inc.,

a Delaware corporation (“Parent” or “Gilead”), issued a press release announcing the completion

of the acquisition of the Arcellx, Inc., a Delaware corporation (the “Company”), a copy of which is attached as

Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information in Item 7.01 and Item 9.01 of

this Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange

Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall

it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of

any general incorporation language in such filing.

Item 8.01.

Other Events.

As previously disclosed, on February 22,

2026, Gilead entered into an Agreement and Plan of Merger (the “Merger Agreement”), among Parent, the Company and Ravens

Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Purchaser”). In accordance with the

terms of the Merger Agreement, on April 28, 2026, Gilead completed the acquisition of the Company.

Pursuant to the Merger Agreement, and upon

the terms and subject to the conditions thereof, on March 6, 2026, Purchaser commenced a tender offer (the “Offer”),

to purchase all of the issued and outstanding shares (the “Shares”) of

common stock, par value $0.001 per share, of the Company (other than any Shares owned immediately prior to the effective time

of the Merger (as defined below) by the Company (including those held in the Company’s treasury), and any Shares owned

both as of the date of the commencement of the Offer and immediately prior to the effective time of the Merger by Parent, Purchaser

or any other direct or indirect wholly owned subsidiary of Parent, at a price per Share of (i) $115.00 per Share (the “Closing

Amount”), net to the seller in cash, without interest, subject to any withholding tax, plus (ii) one

contractual contingent value right (a “CVR”), which represents the right

to receive one contingent payment of $5.00 per CVR, in cash, without interest, and subject to any withholding tax, payable on

March 31, 2030, subject to cumulative worldwide Sales (as defined in the CVR Agreement (as defined below)) of the

Company’s anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029 and

the other terms and conditions set forth in a contingent value rights agreement (the “CVR

Agreement”), entered into by and among Parent, Computershare, Inc., a Delaware corporation, and its affiliate,

Computershare Trust Company, N.A., a federally chartered trust company.

The Offer expired at 5:00 p.m., Eastern Time,

on April 27, 2026 (the ‘‘Expiration Time’’). According to Computershare Trust Company, N.A., the depositary

and paying agent for the Offer, as of the Expiration Time, 38,795,604 Shares were validly tendered and not validly withdrawn in the Offer,

representing, together with Shares already owned by Parent, approximately 77.2% of the outstanding Shares. The number of Shares tendered

satisfied the condition to the Offer that there be validly tendered, and not validly withdrawn, in the Offer a number of Shares that,

considered together with all other Shares owned by Purchaser and its affiliates (as such term is defined in Section 251(h)(6) of

the General Corporation Law of the State of Delaware (the “DGCL”)), represent one more Share than 50% of the total

number of Shares outstanding at the Expiration Time. All conditions to the Offer having been satisfied or waived, Gilead and Purchaser

accepted for payment all Shares validly tendered and not validly withdrawn.

Following the consummation of the Offer, the remaining

conditions to the Merger set forth in the Merger Agreement were satisfied or waived, and on April 28, 2026, Purchaser merged with

and into the Company (the “Merger”) pursuant to Section 251(h) of the DGCL, with the Company continuing as

the surviving corporation and a wholly owned subsidiary of Parent. Each Share outstanding immediately prior to the effective time of the

Merger (other than (i) Shares owned immediately prior to the effective time of the Merger by the Company (including those held in

the Company’s treasury), (ii) Shares owned both as of the commencement of the Offer and immediately prior to the effective

time of the Merger by Parent, Purchaser, or any other direct or indirect wholly owned subsidiary of Parent, (iii) Shares irrevocably

accepted for purchase pursuant to the Offer and (iv) Shares held by stockholders who are entitled to appraisal rights under Section 262

of the DGCL and have properly exercised and perfected their respective demands for appraisal of such Shares in the time and manner provided

in Section 262 of the DGCL and, as of the effective time of the Merger, have neither effectively withdrawn nor lost their rights

to such appraisal and payment under the DGCL) was converted into the right to receive, on a per Share basis, (i) the Closing Amount

in cash, without any interest thereon, subject to any withholding tax, plus (ii) one CVR per Share.

The aggregate amount of funds used by Gilead to

consummate the Offer and Merger (including payments for options, restricted stock units and other payments referred to in the Merger Agreement)

was approximately $7.1 billion.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

The following Exhibit 99.1 is furnished pursuant to this Item

9.01.

Exhibit

Number

Description

99.1

Press Release, dated April 28, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GILEAD SCIENCES, INC.

By:

/s/ Andrew Dickinson

Name:

Andrew Dickinson

Title:

Chief Financial Officer

Dated: April 28, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2612748d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

CONTACTS:

Ashleigh Koss, Media

Public_affairs@gilead.com

Jacquie Ross, Investors

investor_relations@gilead.com

GILEAD SCIENCES COMPLETES ACQUISITION OF ARCELLX

AHEAD OF POTENTIAL COMMERCIAL LAUNCH OF ANITO-CEL

FOSTER CITY, Calif., April 28, 2026 –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of

Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non-transferable

contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of

closing.

The acquisition builds on Kite, a Gilead Company,

and Arcellx’s successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito-cel), an investigational

BCMA-directed CAR T-cell therapy for multiple myeloma. By consolidating ownership of anito-cel and eliminating future profit-share, milestone

and royalty obligations, Gilead is positioned to accelerate development, streamline decision-making and maximize the long-term potential

of the program.

“With the Arcellx acquisition, our focus

turns to executing with speed and discipline as we prepare to bring anito-cel to patients,” said Cindy Perettie, Executive Vice

President and Global Head of Kite. “I want to thank the Arcellx team for their scientific leadership, close collaboration to date

and deep expertise they bring as we advance anito-cel. With this acquisition, anito-cel and the differentiated D-Domain BCMA binder will

advance within Kite, combining this science with our global manufacturing, regulatory and commercial capabilities to unlock the full value

of this potentially transformative therapy for people living with multiple myeloma.”

On April 28, 2026, Gilead successfully completed

its tender offer for all outstanding shares of common stock of Arcellx and accepted for payment all shares validly tendered and not validly

withdrawn as of the expiration time of the tender offer, which shares represented, together with shares already owned by Gilead, approximately

77.2% of Arcellx’s outstanding shares. Following completion of the offer, Gilead completed the acquisition of Arcellx through

a merger of Gilead’s wholly owned subsidiary with and into Arcellx, in which shares of Arcellx common stock were cancelled and

converted into the right to receive the same $115 per share in cash and one CVR of $5 per share as shares tendered in the offer.

The CVR is payable upon achievement of cumulative

global net sales of anito-cel of at least $6.0 billion from launch through the end of 2029.

As a result of the completion of the merger, Arcellx

has become a wholly owned subsidiary of Gilead and the common stock of Arcellx will be delisted from the Nasdaq Global Select Market.

This transaction is expected to be accounted for

as an asset acquisition and reduce Gilead’s GAAP and non-GAAP 2026 diluted EPS by approximately $5.57 - $5.67. Excluding the impact

of acquired in-process research and development expenses, Gilead expects the transaction to be modestly dilutive to earnings per share

in 2026 and 2027, and accretive in 2028 and thereafter, subject to FDA approval of anito-cel.

About Anito-cel

Anitocabtagene autoleucel (anito-cel, previously

ddBCMA) is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes a novel and compact binder

known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly

release from the BCMA target. This combination may allow for the effective elimination of multiple myeloma cells without severe immunotoxicity.

Anito-cel has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the U.S. Food and Drug

Administration.

About Gilead and Kite Oncology

Gilead and Kite Oncology are working to transform

how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for

people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug

conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.

About Gilead Sciences

Gilead Sciences, Inc.

is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating

a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases,

including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further

strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing

to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide,

with headquarters in Foster City, Calif.

Forward-Looking Statements

This communication contains forward-looking statements

related to Gilead, Arcellx and the acquisition of Arcellx by Gilead that are subject to risks, uncertainties, and other factors. All statements

other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding

the intent, belief or current expectation of Gilead and Arcellx and members of their respective senior management teams. In some cases,

forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “estimate,”

“expect,” “intend,” “seek,” “may,” “plan,” “project,” “should,”

“target,” “will,” or the negative of these terms or other similar expressions, although not all forward-looking

statements contain these words. Forward-looking statements include, without limitation, statements regarding the transaction and related

matters, prospective performance and opportunities, post-closing operations and the outlook for the companies’ businesses, including

Gilead’s ability to apply its global manufacturing, regulatory and commercial capabilities and to accelerate the development of

anito-cel; regulatory applications; the potential of Arcellx’s cell therapy platform; the impact of the transaction on Gilead’s

diluted EPS; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are

not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking

statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and

uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: the

effects of the transaction on relationships with employees, other business partners or governmental entities; the difficulty of predicting

the timing or outcome of regulatory approvals or actions, if any; the risk that the businesses will not be integrated successfully and

that other anticipated benefits from the transaction will not be realized; the risk that the milestone associated with the CVR may not

be achieved and that holders of CVRs may not receive payments in respect thereof; the impact of competitive products and pricing;

other business effects, including the effects of industry, economic or political conditions outside of the companies’ control;

transaction costs; actual or contingent liabilities; and other risks and uncertainties detailed from time to time in the companies’

periodic reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including current reports on Form 8-K,

quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 filed by Arcellx and the Schedule

TO and related tender offer documents filed by Gilead and Ravens Sub, Inc., a wholly owned subsidiary of Gilead. All forward-looking

statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update

any such forward-looking statements.

###

Gilead, Kite, Arcellx and the Gilead logo are

trademarks of Gilead Sciences, Inc., or its related companies.

For more information

about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn

(@Gilead-Sciences).

GRAPHIC

Filename: tm2612748d1_ex99-1img001.jpg · Sequence: 6

Binary file (8209 bytes)

Download tm2612748d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 28, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 28, 2026

Entity File Number

0-19731

Entity Registrant Name

GILEAD SCIENCES, INC.

Entity Central Index Key

0000882095

Entity Tax Identification Number

94-3047598

Entity Incorporation, State or Country Code

Entity Address, Address Line One

333 Lakeside Drive

Entity Address, City or Town

Foster City

Entity Address, State or Province

Entity Address, Postal Zip Code

94404

City Area Code

650

Local Phone Number

574-3000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value, $0.001 per share

Trading Symbol

GILD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration